151 related articles for article (PubMed ID: 12959285)
1. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
Hussein Z; Granneman GR; Mukherjee D; Samara E; Hogan DL; Koss MA; Isenberg JI
Br J Clin Pharmacol; 1993 Nov; 36(5):391-8. PubMed ID: 12959285
[TBL] [Abstract][Full Text] [Related]
2. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
3. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
4. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Huang JQ; Goldwater DR; Thomson AB; Appelman SA; Sridhar S; James CF; Chiu YL; Pilmer BL; Keith RG; Hunt RH
Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
8. Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers.
Brunner G; Hell M; Hengels KJ; Hennig U; Fuchs W
Digestion; 1995; 56(2):137-44. PubMed ID: 7750667
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
Freston JW; Pilmer BL; Chiu YL; Wang Q; Stolle JC; Griffin JS; Lee CQ
Aliment Pharmacol Ther; 2004 May; 19(10):1111-22. PubMed ID: 15142201
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
[TBL] [Abstract][Full Text] [Related]
12. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Barclay ML; Begg EJ; Robson RA; Peters WA; Ketelbey JW
Aliment Pharmacol Ther; 1999 Sep; 13(9):1215-9. PubMed ID: 10468704
[TBL] [Abstract][Full Text] [Related]
13. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Bell NJ; Hunt RH
Aliment Pharmacol Ther; 1996 Dec; 10(6):897-904. PubMed ID: 8971286
[TBL] [Abstract][Full Text] [Related]
14. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
Müller P; Göksu MA; Fuchs W; Schlüter F; Simon B
Aliment Pharmacol Ther; 2000 Sep; 14(9):1225-9. PubMed ID: 10971240
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
[TBL] [Abstract][Full Text] [Related]
16. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of lansoprazole.
Landes BD; Petite JP; Flouvat B
Clin Pharmacokinet; 1995 Jun; 28(6):458-70. PubMed ID: 7656504
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Gunasekaran T; Gupta S; Gremse D; Karol M; Pan WJ; Chiu YL; Keith R; Fitzgerald J
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S327-35. PubMed ID: 12607793
[TBL] [Abstract][Full Text] [Related]
20. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole.
Thoring M; Hedenström H; Eriksson LS
Scand J Gastroenterol; 1999 Apr; 34(4):341-5. PubMed ID: 10365892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
